Zynerba Pharmaceuticals, Inc. (ZYNE)
After hours:
| Previous close | 0.6106 |
| Open | 0.6400 |
| Bid | 0.6301 x 1200 |
| Ask | 0.6288 x 1100 |
| Day's range | 0.6011 - 0.6400 |
| 52-week range | 0.4900 - 2.9400 |
| Volume | |
| Avg. volume | 321,363 |
| Market cap | 29.659M |
| Beta (5Y monthly) | 1.66 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.9620 |
| Earnings date | 27 Feb 2023 - 03 Mar 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 5.44 |
- GlobeNewswire
Zynerba Pharmaceuticals Announces Publication in the Journal of Neurodevelopmental Disorders Describing the Role of the Endocannabinoid System and Cannabidiol Therapy in Fragile X Syndrome
Comprehensive data review suggests a central role for the endocannabinoid system (ECS) in neuronal development, cognitive function and in the pathogenesis of Fragile X syndrome (FXS) Cannabidiol may help restore the function of the ECS in FXS patients according to review of data Consistent with the proposed mechanisms of action of cannabidiol in FXS, Zygel™ showed a significant reduction in behavioral symptoms, in patients with ≥90% methylation of the FMR1 gene, compared to those treated with pl
- Simply Wall St.
Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Invest In Growth?
We can readily understand why investors are attracted to unprofitable companies. For example, although...
- GlobeNewswire
Zynerba Pharmaceuticals Announces Update on RECONNECT, the Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome
RECONNECT initial screening visits are being adversely impacted by environmental factors, such as the “Tripledemic” (high rates of RSV, influenza and COVID-19); topline results now expected first half of 2024 Cash runway extended to mid-year 2024 due to prioritization of resources on the completion of the RECONNECT trial DEVON, Pa., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies
